BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma grants 63,009 inducement RSUs to 36 new hires under its amended equity incentive plan.

Rhea-AI Summary

BridgeBio Pharma (BBIO) granted equity awards under Nasdaq Listing Rule 5635(c)(4) to 36 new employees, effective September 18, 2026.

The compensation committee approved restricted stock unit grants covering an aggregate of 63,009 common shares. For each employee, one-fourth of the RSU award will vest on November 16, 2027, and the remaining three-fourths will vest in equal quarterly installments over three years thereafter, subject to continued employment with BridgeBio or its subsidiaries on each vesting date. The inducement awards were granted under the company’s equity plan, originally adopted in November 2019 and amended and restated on February 10, 2023 and December 13, 2023.

News Explained

The approved awards cover 63,009 common shares, with vesting beginning on November 16, 2027 and conditioned on continued employment; if they vest, those shares can dilute existing holders’ proportional ownership.

Key Figures

Employees receiving grants: 36 employees Shares granted: 63,009 shares Initial vesting date: November 16, 2027 +1 more

Employees receiving grants

36 employees

New employees

Shares granted

63,009 shares

Aggregate restricted stock unit grants

Initial vesting date

November 16, 2027

One-fourth of shares underlying each grant

Subsequent vesting schedule

One-twelfth quarterly

Remaining shares after initial vesting

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"approved equity grants to 36 new employees in restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on September 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 63,009 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com